In patients with stage III melanoma, the overall risk for relapse is 50% over 5-10 years. Thus, adjuvant therapy should be considered in any patients with stage III A, B, C, or D disease, as well as in patients with resected stage IV disease. When choosing to treat with adjuvant therapy, clinicians should consider several factors, including stage, burden of disease, comorbidities, and age.
Learn more about adjuvant therapy for melanoma.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Chih-Shan Jason Chen. Fast Five Quiz: Melanoma Treatment - Medscape - Jan 24, 2020.